ZRO is trading at $2.02, down 0.53% over 24 hours, so the immediate price signal is mildly negative rather than decisively bearish. It is in the upper portion of the $1.89–$2.06 daily range, $0.04 below the high, showing a partial recovery from the session low but not a positive daily close.

The hourly moving averages provide a mixed but slightly constructive short-term picture: price is above the 8-, 13-, and 21-hour averages at $1.98, $1.97, and $1.97, respectively. It is approximately at the 55-hour average of $2.02 but below the 144-hour average of $2.07, so short-term strength has not cleared the longer hourly trend measure.

Momentum readings also lean modestly positive in the immediate term, with the 1-hour RSI at 64. The 7-day RSI of 51 is near neutral, however, and does not confirm strong broader momentum; together, these readings suggest short-term firmness without a strong momentum signal across time frames.

The multiweek price changes are a stronger bullish factor: ZRO is up 26.85% over 14 days and 92.44% over 30 days. The 7-day change is negative at 3.56%, indicating that the shorter window has weakened within the larger advance and making recent gains less consistent.

That divergence matters for the rating: the 30-day rise shows substantial positive momentum, but the latest daily and weekly changes point to a pullback. The price’s position above the short hourly averages supports the possibility of stabilization, while its position below the 144-hour average argues against treating the recovery as fully confirmed.

Reported 24-hour volume is 71,143,677, with volume equal to 8.82% of market capitalization. This establishes meaningful current trading activity in absolute terms, but without a historical volume comparison it cannot show whether participation is increasing or validate the recent price move.

ZRO remains about 73% below its $7.47 all-time high, recorded on December 6, 2024. That distance provides historical context but does not, by itself, establish either a current recovery path or further downside; the supplied near-term indicators are more useful for the present assessment.

Overall rating: Hold. The primary evidence is the strong 14- and 30-day gains and price above the three shortest hourly averages, balanced against the negative 7-day and 24-hour changes, neutral weekly RSI, and price below the 144-hour average. This mix favors waiting for clearer confirmation rather than assigning a Buy or Sell rating.